While in vivo CAR-T therapies eliminate complex ex vivo manufacturing, they introduce a new critical variable: the patient's own immune system. The therapy's efficacy relies on modifying T-cells within the body, but each patient's immune status is different, especially after prior treatments. This makes optimizing and standardizing the dose a significant challenge compared to engineered cell therapies.

An investigational in vivo CAR-T therapy uses viral particles infused directly into the patient to convert their T-cells into CAR-T cells. This approach eliminates the complex steps of apheresis, lymphodepletion, and ex vivo manufacturing, effectively creating an off-the-shelf product that becomes an autologous treatment inside the body.

While personalized cancer vaccines require extracting and processing a patient's tumor, Create Medicines' in vivo approach is entirely off-the-shelf. By delivering the programming directly into the body, they enable the patient's own immune system to do the complex, personalized work of attacking the cancer itself.

Early data from an in vivo CAR-T therapy suggests a paradigm shift is possible. By engineering T-cells directly inside the patient with a simple infusion, this approach could eliminate the need for leukapheresis and external manufacturing, completely disrupting the current cell therapy model.

While many cell therapies rely on complex genetic engineering with viral vectors, Adaptin Bio manipulates patient T-cells without it. This simpler, non-viral process is a strategic choice to reduce costs, speed up manufacturing, and make the therapy accessible to a broader patient population.

Contrary to the belief that CAR-T therapies require inpatient hospitalization, about 50% of Carvykti infusions occur in an outpatient setting. This flexibility allows more hospitals to offer the treatment and makes it more accessible for patients, revolutionizing the delivery model for complex cell therapies.

Many current gene therapies require a complex "ex vivo" process: removing cells, reprogramming them in a lab, and reinfusing them. The true breakthrough is developing "in vivo" treatments administered via a simple infusion that autonomously target the correct cells within the body.

The commercial challenges of Bluebird Bio's "single therapy for a single patient" model were a key catalyst for the industry's evolution. This reality pushed the field toward developing more economically viable and broadly applicable technologies, like in vivo CAR-T, that can reach more patients globally.

While in vivo CAR-T could eliminate complex manufacturing, it lacks the safety guardrails of ex vivo methods. Clinicians cannot monitor the effective dose, count viral integrations, or guarantee that only T cells are engineered, posing significant risks of uncontrolled off-target effects.